Fortrea Holdings Inc. (FTRE)
| Market Cap | 1.01B |
| Revenue (ttm) | 2.72B |
| Net Income (ttm) | -986.20M |
| Shares Out | 93.50M |
| EPS (ttm) | -10.81 |
| PE Ratio | n/a |
| Forward PE | 15.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,491,227 |
| Open | 10.65 |
| Previous Close | 10.60 |
| Day's Range | 10.47 - 10.89 |
| 52-Week Range | 3.97 - 18.67 |
| Beta | 1.77 |
| Analysts | Buy |
| Price Target | 14.06 (+30.67%) |
| Earnings Date | May 5, 2026 |
About FTRE
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, ... [Read more]
Financial Performance
In 2025, Fortrea Holdings's revenue was $2.72 billion, an increase of 1.00% compared to the previous year's $2.70 billion. Losses were -$986.20 million, 200.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for FTRE stock is "Buy." The 12-month stock price target is $14.06, which is an increase of 30.67% from the latest price.
News
Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2...
Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials
Highlights: Designed to transform clinical trial operations for sponsors, sites and study teams Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial s...
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restric...
Fortrea Holdings Earnings Call Transcript: Q4 2025
Revenue and Adjusted EBITDA met guidance for 2025, with strong cash flow and cost savings. 2026 guidance anticipates stable revenue, margin improvement, and continued cost optimization, supported by improved biotech funding and operational efficiency.
Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
Revenue and Adjusted EBITDA results delivered in line with stated full-year targets Full‑year cost savings exceeded previously communicated targets
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients Adds to executive focus on early clinical development and deepens medical and scientif...
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter a...
Fortrea Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortrea Holdings, Inc. - FTRE
NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Fortrea Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
Emerging from its spin-off, the company is leveraging decades of expertise and technology to modernize clinical trial delivery, focusing on execution, margin expansion, and sustainable growth. Optimism in pharma R&D investment and disciplined capital allocation support its multi-year strategy.
Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, ...
Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of I...
SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global cont...
Fortrea Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference
Leadership transition is progressing well, with strategic changes underway and a focus on growth through new customer acquisition and operational improvements. Market sentiment is improving, technology innovation is driving efficiency, and cost discipline is supporting margin expansion and leverage reduction.
Fortrea Holdings Transcript: Citi Annual Global Healthcare Conference 2025
Sequential improvement in bookings and strong pipeline momentum are supported by operational changes, cost actions, and a bespoke client model. Financial guidance is raised, debt reduction continues, and margin expansion is targeted through efficiency and disciplined pricing.
Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief finan...
Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand
DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender off...
Fortrea Appoints Agnieszka Gallagher as General Counsel
DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M.
Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer
DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief R...
Fortrea Holdings Earnings Call Transcript: Q3 2025
Q3 2025 saw revenue of $701.3M and adjusted EBITDA of $50.7M, with improved win rates and a book-to-bill ratio of 1.13. Raised full-year revenue guidance and continued cost optimization, while maintaining strong liquidity and focusing on margin improvement.
Fortrea Reports Third Quarter 2025 Results
For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 million GAAP net loss of $(15.9) million Adjusted EBITDA of $50.7 million GAAP and adjusted net (loss) inc...
Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call
DURHAM, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its third quarter 20...
Fortrea Appoints William Sharbaugh to Board of Directors
DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to ...
Investors who lost money with Fortrea Holdings Inc. (NASDAQ: FTRE) should contact the Shareholders Foundation in connection with Lawsuit
SAN DIEGO , Aug. 25, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NASDAQ: FTRE shares over alleged securities laws violations by Fort...
Fortrea Holdings Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 7.2% year-over-year to $710.3 million, with adjusted EBITDA of $54.9 million and a raised full-year revenue outlook. A $309.1 million goodwill impairment drove a net loss, but operational improvements, cost savings, and strong clinical pharmacology performance support a positive outlook.
Fortrea Reports Second Quarter 2025 Results
For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 million GAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment charge Adjusted EBITDA o...